Serveur d'exploration sur la rapamycine et les champignons

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain.

Identifieur interne : 001666 ( Main/Exploration ); précédent : 001665; suivant : 001667

The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain.

Auteurs : Sarah R. Edwards [États-Unis] ; Thomas J. Wandless

Source :

RBID : pubmed:17350953

Descripteurs français

English descriptors

Abstract

Rapamycin is an immunosuppressive drug that binds simultaneously to the 12-kDa FK506- and rapamycin-binding protein (FKBP12, or FKBP) and the FKBP-rapamycin binding (FRB) domain of the mammalian target of rapamycin (mTOR) kinase. The resulting ternary complex has been used to conditionally perturb protein function, and one such method involves perturbation of a protein of interest through its mislocalization. We synthesized two rapamycin derivatives that possess large substituents at the C-16 position within the FRB-binding interface, and these derivatives were screened against a library of FRB mutants using a three-hybrid assay in Saccharomyces cerevisiae. Several FRB mutants responded to one of the rapamycin derivatives, and twenty of these mutants were further characterized in mammalian cells. The mutants most responsive to the ligand were fused to yellow fluorescent protein, and fluorescence levels in the presence and absence of the ligand were measured to determine stability of the fusion proteins. Wild-type and mutant FRB domains were expressed at low levels in the absence of the rapamycin derivative, and expression levels rose up to 10-fold upon treatment with ligand. The synthetic rapamycin derivatives were further analyzed using quantitative mass spectrometry, and one of the compounds was found to contain contaminating rapamycin. Furthermore, uncontaminated analogs retained the ability to inhibit mTOR, although with diminished potency relative to rapamycin. The ligand-dependent stability displayed by wild-type FRB and FRB mutants as well as the inhibitory potential and purity of the rapamycin derivatives should be considered as potentially confounding experimental variables when using these systems.

DOI: 10.1074/jbc.M700498200
PubMed: 17350953
PubMed Central: PMC3763840


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain.</title>
<author>
<name sortKey="Edwards, Sarah R" sort="Edwards, Sarah R" uniqKey="Edwards S" first="Sarah R" last="Edwards">Sarah R. Edwards</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Chemistry, Stanford University, Stanford, California 94305, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Chemistry, Stanford University, Stanford, California 94305</wicri:regionArea>
<wicri:noRegion>California 94305</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Wandless, Thomas J" sort="Wandless, Thomas J" uniqKey="Wandless T" first="Thomas J" last="Wandless">Thomas J. Wandless</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2007">2007</date>
<idno type="RBID">pubmed:17350953</idno>
<idno type="pmid">17350953</idno>
<idno type="doi">10.1074/jbc.M700498200</idno>
<idno type="pmc">PMC3763840</idno>
<idno type="wicri:Area/Main/Corpus">001719</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001719</idno>
<idno type="wicri:Area/Main/Curation">001719</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001719</idno>
<idno type="wicri:Area/Main/Exploration">001719</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain.</title>
<author>
<name sortKey="Edwards, Sarah R" sort="Edwards, Sarah R" uniqKey="Edwards S" first="Sarah R" last="Edwards">Sarah R. Edwards</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Chemistry, Stanford University, Stanford, California 94305, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Chemistry, Stanford University, Stanford, California 94305</wicri:regionArea>
<wicri:noRegion>California 94305</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Wandless, Thomas J" sort="Wandless, Thomas J" uniqKey="Wandless T" first="Thomas J" last="Wandless">Thomas J. Wandless</name>
</author>
</analytic>
<series>
<title level="j">The Journal of biological chemistry</title>
<idno type="ISSN">0021-9258</idno>
<imprint>
<date when="2007" type="published">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Amino Acid Motifs (genetics)</term>
<term>Animals (MeSH)</term>
<term>Enzyme Stability (drug effects)</term>
<term>Enzyme Stability (genetics)</term>
<term>Immunosuppressive Agents (pharmacology)</term>
<term>Ligands (MeSH)</term>
<term>Mass Spectrometry (MeSH)</term>
<term>Mice (MeSH)</term>
<term>Mutation (MeSH)</term>
<term>NIH 3T3 Cells (MeSH)</term>
<term>Protein Binding (drug effects)</term>
<term>Protein Binding (genetics)</term>
<term>Protein Kinases (genetics)</term>
<term>Protein Kinases (metabolism)</term>
<term>Protein Structure, Quaternary (drug effects)</term>
<term>Saccharomyces cerevisiae (genetics)</term>
<term>Sirolimus (analogs & derivatives)</term>
<term>Sirolimus (pharmacology)</term>
<term>TOR Serine-Threonine Kinases (MeSH)</term>
<term>Tacrolimus Binding Protein 1A (genetics)</term>
<term>Tacrolimus Binding Protein 1A (metabolism)</term>
<term>Two-Hybrid System Techniques (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Animaux (MeSH)</term>
<term>Cellules NIH 3T3 (MeSH)</term>
<term>Immunosuppresseurs (pharmacologie)</term>
<term>Liaison aux protéines (effets des médicaments et des substances chimiques)</term>
<term>Liaison aux protéines (génétique)</term>
<term>Ligands (MeSH)</term>
<term>Motifs d'acides aminés (génétique)</term>
<term>Mutation (MeSH)</term>
<term>Protein kinases (génétique)</term>
<term>Protein kinases (métabolisme)</term>
<term>Protéine 1A de liaison au tacrolimus (génétique)</term>
<term>Protéine 1A de liaison au tacrolimus (métabolisme)</term>
<term>Saccharomyces cerevisiae (génétique)</term>
<term>Sirolimus (analogues et dérivés)</term>
<term>Sirolimus (pharmacologie)</term>
<term>Souris (MeSH)</term>
<term>Spectrométrie de masse (MeSH)</term>
<term>Stabilité enzymatique (effets des médicaments et des substances chimiques)</term>
<term>Stabilité enzymatique (génétique)</term>
<term>Structure quaternaire des protéines (effets des médicaments et des substances chimiques)</term>
<term>Sérine-thréonine kinases TOR (MeSH)</term>
<term>Techniques de double hybride (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en">
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en">
<term>Protein Kinases</term>
<term>Tacrolimus Binding Protein 1A</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Protein Kinases</term>
<term>Tacrolimus Binding Protein 1A</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en">
<term>Immunosuppressive Agents</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr">
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Enzyme Stability</term>
<term>Protein Binding</term>
<term>Protein Structure, Quaternary</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr">
<term>Liaison aux protéines</term>
<term>Stabilité enzymatique</term>
<term>Structure quaternaire des protéines</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en">
<term>Amino Acid Motifs</term>
<term>Enzyme Stability</term>
<term>Protein Binding</term>
<term>Saccharomyces cerevisiae</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr">
<term>Liaison aux protéines</term>
<term>Motifs d'acides aminés</term>
<term>Protein kinases</term>
<term>Protéine 1A de liaison au tacrolimus</term>
<term>Saccharomyces cerevisiae</term>
<term>Stabilité enzymatique</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr">
<term>Protein kinases</term>
<term>Protéine 1A de liaison au tacrolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr">
<term>Immunosuppresseurs</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Ligands</term>
<term>Mass Spectrometry</term>
<term>Mice</term>
<term>Mutation</term>
<term>NIH 3T3 Cells</term>
<term>TOR Serine-Threonine Kinases</term>
<term>Two-Hybrid System Techniques</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Animaux</term>
<term>Cellules NIH 3T3</term>
<term>Ligands</term>
<term>Mutation</term>
<term>Souris</term>
<term>Spectrométrie de masse</term>
<term>Sérine-thréonine kinases TOR</term>
<term>Techniques de double hybride</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Rapamycin is an immunosuppressive drug that binds simultaneously to the 12-kDa FK506- and rapamycin-binding protein (FKBP12, or FKBP) and the FKBP-rapamycin binding (FRB) domain of the mammalian target of rapamycin (mTOR) kinase. The resulting ternary complex has been used to conditionally perturb protein function, and one such method involves perturbation of a protein of interest through its mislocalization. We synthesized two rapamycin derivatives that possess large substituents at the C-16 position within the FRB-binding interface, and these derivatives were screened against a library of FRB mutants using a three-hybrid assay in Saccharomyces cerevisiae. Several FRB mutants responded to one of the rapamycin derivatives, and twenty of these mutants were further characterized in mammalian cells. The mutants most responsive to the ligand were fused to yellow fluorescent protein, and fluorescence levels in the presence and absence of the ligand were measured to determine stability of the fusion proteins. Wild-type and mutant FRB domains were expressed at low levels in the absence of the rapamycin derivative, and expression levels rose up to 10-fold upon treatment with ligand. The synthetic rapamycin derivatives were further analyzed using quantitative mass spectrometry, and one of the compounds was found to contain contaminating rapamycin. Furthermore, uncontaminated analogs retained the ability to inhibit mTOR, although with diminished potency relative to rapamycin. The ligand-dependent stability displayed by wild-type FRB and FRB mutants as well as the inhibitory potential and purity of the rapamycin derivatives should be considered as potentially confounding experimental variables when using these systems.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">17350953</PMID>
<DateCompleted>
<Year>2007</Year>
<Month>06</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">0021-9258</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>282</Volume>
<Issue>18</Issue>
<PubDate>
<Year>2007</Year>
<Month>May</Month>
<Day>04</Day>
</PubDate>
</JournalIssue>
<Title>The Journal of biological chemistry</Title>
<ISOAbbreviation>J Biol Chem</ISOAbbreviation>
</Journal>
<ArticleTitle>The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain.</ArticleTitle>
<Pagination>
<MedlinePgn>13395-401</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Rapamycin is an immunosuppressive drug that binds simultaneously to the 12-kDa FK506- and rapamycin-binding protein (FKBP12, or FKBP) and the FKBP-rapamycin binding (FRB) domain of the mammalian target of rapamycin (mTOR) kinase. The resulting ternary complex has been used to conditionally perturb protein function, and one such method involves perturbation of a protein of interest through its mislocalization. We synthesized two rapamycin derivatives that possess large substituents at the C-16 position within the FRB-binding interface, and these derivatives were screened against a library of FRB mutants using a three-hybrid assay in Saccharomyces cerevisiae. Several FRB mutants responded to one of the rapamycin derivatives, and twenty of these mutants were further characterized in mammalian cells. The mutants most responsive to the ligand were fused to yellow fluorescent protein, and fluorescence levels in the presence and absence of the ligand were measured to determine stability of the fusion proteins. Wild-type and mutant FRB domains were expressed at low levels in the absence of the rapamycin derivative, and expression levels rose up to 10-fold upon treatment with ligand. The synthetic rapamycin derivatives were further analyzed using quantitative mass spectrometry, and one of the compounds was found to contain contaminating rapamycin. Furthermore, uncontaminated analogs retained the ability to inhibit mTOR, although with diminished potency relative to rapamycin. The ligand-dependent stability displayed by wild-type FRB and FRB mutants as well as the inhibitory potential and purity of the rapamycin derivatives should be considered as potentially confounding experimental variables when using these systems.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Edwards</LastName>
<ForeName>Sarah R</ForeName>
<Initials>SR</Initials>
<AffiliationInfo>
<Affiliation>Department of Chemistry, Stanford University, Stanford, California 94305, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wandless</LastName>
<ForeName>Thomas J</ForeName>
<Initials>TJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01 GM068589-03</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>GM068589</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 GM068589-04</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 GM068589</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 GM068589-05</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2007</Year>
<Month>03</Month>
<Day>09</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Biol Chem</MedlineTA>
<NlmUniqueID>2985121R</NlmUniqueID>
<ISSNLinking>0021-9258</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008024">Ligands</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.-</RegistryNumber>
<NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="C546843">mTOR protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 5.2.1.-</RegistryNumber>
<NameOfSubstance UI="D022061">Tacrolimus Binding Protein 1A</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>W36ZG6FT64</RegistryNumber>
<NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D020816" MajorTopicYN="N">Amino Acid Motifs</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004795" MajorTopicYN="N">Enzyme Stability</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D041681" MajorTopicYN="N">NIH 3T3 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011494" MajorTopicYN="N">Protein Kinases</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D020836" MajorTopicYN="N">Protein Structure, Quaternary</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D012441" MajorTopicYN="N">Saccharomyces cerevisiae</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D022061" MajorTopicYN="N">Tacrolimus Binding Protein 1A</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D020798" MajorTopicYN="N">Two-Hybrid System Techniques</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="pubmed">
<Year>2007</Year>
<Month>3</Month>
<Day>14</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2007</Year>
<Month>6</Month>
<Day>15</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2007</Year>
<Month>3</Month>
<Day>14</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">17350953</ArticleId>
<ArticleId IdType="pii">M700498200</ArticleId>
<ArticleId IdType="doi">10.1074/jbc.M700498200</ArticleId>
<ArticleId IdType="pmc">PMC3763840</ArticleId>
<ArticleId IdType="mid">NIHMS357876</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Curr Biol. 1997 Sep 1;7(9):638-44</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9285717</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Chem Biol. 1995 Jul;2(7):471-81</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9383449</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nature. 1998 Feb 19;391(6669):806-11</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9486653</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Curr Biol. 1998 Feb 26;8(5):257-66</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9501066</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 1999 Feb 12;274(7):4266-72</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9933627</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Methods. 2005 Jun;2(6):415-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15908919</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Exp Cell Res. 2005 Sep 10;309(1):211-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15963500</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Chem Biol. 2006 Jan;13(1):99-107</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16426976</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 2006 Sep 8;126(5):995-1004</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16959577</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 2006 Dec 1;314(5804):1454-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16990515</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 2006 Dec 1;314(5804):1458-61</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17095657</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3565-70</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9108016</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 2000 Aug 18;275(33):25381-90</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10801867</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Methods Enzymol. 2002;350:87-96</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12073338</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell. 2003 Dec;12(6):1615-24</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14690613</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nature. 1994 Jun 30;369(6483):756-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8008069</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9302-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7937760</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Mol Biol. 1996 Feb 2;255(4):589-603</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8568899</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nature. 1996 Aug 29;382(6594):822-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8752278</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):12817-21</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8917502</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):7825-30</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9223271</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>États-Unis</li>
</country>
</list>
<tree>
<noCountry>
<name sortKey="Wandless, Thomas J" sort="Wandless, Thomas J" uniqKey="Wandless T" first="Thomas J" last="Wandless">Thomas J. Wandless</name>
</noCountry>
<country name="États-Unis">
<noRegion>
<name sortKey="Edwards, Sarah R" sort="Edwards, Sarah R" uniqKey="Edwards S" first="Sarah R" last="Edwards">Sarah R. Edwards</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001666 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001666 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    RapamycinFungusV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:17350953
   |texte=   The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:17350953" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a RapamycinFungusV1 

Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Thu Nov 19 21:55:41 2020. Site generation: Thu Nov 19 22:00:39 2020